JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maynert, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maynert, E. W.
Journal of Pharmacology And Experimental Therapeutics, Vol. 150, Issue 1, 118-121, 1965
Copyright © 1965 by American Society for Pharmacology and Experimental Therapeutics


THE ALCOHOLIC METABOLITES OF PENTOBARBITAL AND AMOBARBITAL IN MAN

E. W. Maynert 1

1 Department of Pharmacology and Experimental Therapeutics, The Johns Hopkins University, School of Medicine, Baltimore, Maryland

In normal human subjects the metabolites of 100- to 500-mg doses of N15-labeled pentobarbital or amobarbital were gradually eliminated in the urine over the course of 5 days. Isotope dilution experiments revealed that 51 to 73% of the N15 excreted after a 500-mg dose of amobarbital could be accounted for as 5-ethyl-5-(3-hydroxy-3-methyl) barbituric acid. The dextrorotatory and levorotatory diastereoisomers of 5-ethyl-5-(3-hydroxy-1-methyl butyl)barbituric acid accounted for 7 to 8% and 40 to 43%, respectively, of the urinary isotope derived from a 500-mg dose of pentobarbital.

Accepted on April 21, 1965







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics.